Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/00
C07K-007/64
A61K-047/48
C07K-007/08
A61K-031/192
A61K-031/519
A61K-038/10
출원번호
US-0228843
(2014-03-28)
등록번호
US-9238677
(2016-01-19)
발명자
/ 주소
Shailubhai, Kunwar
Jacob, Gary S.
출원인 / 주소
SYNERGY PHARMACEUTICALS, INC.
대리인 / 주소
Kozakiewicz, Cynthia
인용정보
피인용 횟수 :
10인용 특허 :
31
초록▼
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
대표청구항▼
1. A peptide consisting essentially of the amino acid sequence of SEQ ID NO:16. 2. A pharmaceutical composition in unit dose form comprising a guanylate cyclase receptor agonist peptide having the sequence of SEQ ID NO:16 present in a therapeutically effective amount and a pharmaceutical carrier, ex
1. A peptide consisting essentially of the amino acid sequence of SEQ ID NO:16. 2. A pharmaceutical composition in unit dose form comprising a guanylate cyclase receptor agonist peptide having the sequence of SEQ ID NO:16 present in a therapeutically effective amount and a pharmaceutical carrier, excipient or diluent. 3. The pharmaceutical composition of claim 2, wherein the unit dose form is selected from the group consisting of a tablet, a capsule, a solution and inhalation formulation. 4. A method for treating a condition selected from the group consisting of Ulcerative Colitis, Irritable bowel syndrome (IBS), non-ulcer dyspepsia chronic intestinal pseudo-obstruction, functional dyspepsia, colonic pseudo-obstruction, duodenogastric reflux, constipation associated with use of opiate pain killers, gastroesophageal reflux disease (GERD), post surgical constipation, gastroparesis, constipation associated with neuropathic disorders, heartburn, poor gastrointestinal motility , congestive heart failure, hypertension, bronchitis, tissue inflammation, organ inflammation, respiratory inflammation, asthma, and COPD comprising administering to a patient in need thereof, an effective dosage of a guanylate cyclase receptor agonist having the sequence of SEQ ID NO:16. 5. The method of claim 4, further comprising administering an effective dose of a cGMP-dependent phosphodiesterase inhibitor. 6. The method of claim 5, further comprising administering to said patient an effective dose of a cGMP-dependent phosphodiesterase inhibitor either concurrently or sequentially with said guanylate cyclase receptor agonist. 7. The method of claim 6, wherein said cGMP-dependent phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil. 8. The method of claim 5, further comprising administering an effective does of at least one anti-inflammatory agent. 9. The method of claim 8, wherein said anti-inflammatory agent is a steroid or nonsteroid anti-inflammatory drug (NSAID). 10. A method of increasing cGMP production in a cell comprising contacting said cell with a peptide comprising the amino acid sequence of SEQ ID NO:16. 11. The method of claim 10, further comprising contacting said cell with a cGMP-dependent phosphodiesterase inhibitor. 12. The method of claim 11, wherein said cGMP-dependent phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar, Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases.
Jacob, Gary S.; Nikiforovich, Gregory; Shailubhai, Kunwar, Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis.
Shailubhai, Kunwar; Nikiforovich, Gregory; Jacob, Gary S., Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis.
Shailubhai, Kunwar; Nikiforovich, Gregory; Jacob, Gary S., Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis.
Shailubhai,Kunwar; Nikiforovich,Gregory; Jacob,Gary S., Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis.
Bovy Philippe R. (St. Louis MO) Manning Robert E. (St. Louis MO) O\Neal Joan M. (St. Louis MO), Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents.
Mickle,Travis; Krishnan,Suma; Moncrief,James Scott; Lauderback,Christopher; Mickle,Christal, Pharmaceutical compositions for prevention of overdose or abuse.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar; Jacob, Gary S., Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
Shailubhai, Kunwar, Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.